Literature DB >> 26984723

Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.

Anne-Laure Favier1, Evelyne Gout2,3,4, Olivier Reynard5, Olivier Ferraris6, Jean-Philippe Kleman2,3,4, Viktor Volchkov5, Christophe Peyrefitte6, Nicole M Thielens2,3,4.   

Abstract

UNLABELLED: Ebola virus infection requires the surface viral glycoprotein to initiate entry into the target cells. The trimeric glycoprotein is a highly glycosylated viral protein which has been shown to interact with host C-type lectin receptors and the soluble complement recognition protein mannose-binding lectin, thereby enhancing viral infection. Similarly to mannose-binding lectin, ficolins are soluble effectors of the innate immune system that recognize particular glycans at the pathogen surface. In this study, we demonstrate that ficolin-1 interacts with the Zaire Ebola virus (EBOV) glycoprotein, and we characterized this interaction by surface plasmon resonance spectroscopy. Ficolin-1 was shown to bind to the viral glycoprotein with a high affinity. This interaction was mediated by the fibrinogen-like recognition domain of ficolin-1 and the mucin-like domain of the viral glycoprotein. Using a ficolin-1 control mutant devoid of sialic acid-binding capacity, we identified sialylated moieties of the mucin domain to be potential ligands on the glycoprotein. In cell culture, using both pseudotyped viruses and EBOV, ficolin-1 was shown to enhance EBOV infection independently of the serum complement. We also observed that ficolin-1 enhanced EBOV infection on human monocyte-derived macrophages, described to be major viral target cells,. Competition experiments suggested that although ficolin-1 and mannose-binding lectin recognized different carbohydrate moieties on the EBOV glycoprotein, the observed enhancement of the infection likely depended on a common cellular receptor/partner. In conclusion, ficolin-1 could provide an alternative receptor-mediated mechanism for enhancing EBOV infection, thereby contributing to viral subversion of the host innate immune system. IMPORTANCE: A specific interaction involving ficolin-1 (M-ficolin), a soluble effector of the innate immune response, and the glycoprotein (GP) of EBOV was identified. Ficolin-1 enhanced virus infection instead of tipping the balance toward its elimination. An interaction between the fibrinogen-like recognition domain of ficolin-1 and the mucin-like domain of Ebola virus GP occurred. In this model, the enhancement of infection was shown to be independent of the serum complement. The facilitation of EBOV entry into target host cells by the interaction with ficolin-1 and other host lectins shunts virus elimination, which likely facilitates the survival of the virus in infected host cells and contributes to the virus strategy to subvert the innate immune response.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26984723      PMCID: PMC4934759          DOI: 10.1128/JVI.00232-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.

Authors:  Jens H Kuhn; Sheli R Radoshitzky; Alexander C Guth; Kelly L Warfield; Wenhui Li; Martin J Vincent; Jonathan S Towner; Stuart T Nichol; Sina Bavari; Hyeryun Choe; M Javad Aman; Michael Farzan
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

2.  Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein.

Authors:  Jeffrey E Lee; Marnie L Fusco; Dafna M Abelson; Ann J Hessell; Dennis R Burton; Erica Ollmann Saphire
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-10-22

3.  The double life of M-ficolin: what functions when circulating in serum and tethered to leukocyte surfaces?

Authors:  Nicole M Thielens
Journal:  J Leukoc Biol       Date:  2011-09       Impact factor: 4.962

4.  [A first outbreak of Ebola virus in West Africa].

Authors:  Olivier Reynard; Viktor Volchkov; Christophe Peyrefitte
Journal:  Med Sci (Paris)       Date:  2014-07-11       Impact factor: 0.818

5.  Innovative use of a bacterial enzyme involved in sialic acid degradation to initiate sialic acid biosynthesis in glycoengineered insect cells.

Authors:  Christoph Geisler; Donald L Jarvis
Journal:  Metab Eng       Date:  2012-09-27       Impact factor: 9.783

6.  L-ficolin binds to the glycoproteins hemagglutinin and neuraminidase and inhibits influenza A virus infection both in vitro and in vivo.

Authors:  Qin Pan; Haidan Chen; Feng Wang; Victor Tunje Jeza; Wei Hou; Yinglan Zhao; Tian Xiang; Ying Zhu; Yuchi Endo; Teizo Fujita; Xiao-Lian Zhang
Journal:  J Innate Immun       Date:  2012-03-02       Impact factor: 7.349

7.  Deciphering complement receptor type 1 interactions with recognition proteins of the lectin complement pathway.

Authors:  Mickaël Jacquet; Monique Lacroix; Sarah Ancelet; Evelyne Gout; Christine Gaboriaud; Nicole M Thielens; Véronique Rossi
Journal:  J Immunol       Date:  2013-03-04       Impact factor: 5.422

8.  Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.

Authors:  George Lin; Graham Simmons; Stefan Pöhlmann; Frédéric Baribaud; Houping Ni; George J Leslie; Beth S Haggarty; Paul Bates; Drew Weissman; James A Hoxie; Robert W Doms
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses.

Authors:  Anamika Verma; Mitchell White; Vinod Vathipadiekal; Shweta Tripathi; Julvet Mbianda; Micheal Ieong; Li Qi; Jeffery K Taubenberger; Kazue Takahashi; Jens C Jensenius; Steffen Thiel; Kevan L Hartshorn
Journal:  J Immunol       Date:  2012-07-30       Impact factor: 5.422

10.  Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

Authors:  Mohamed R Hamed; Richard J P Brown; Carsten Zothner; Richard A Urbanowicz; Christopher P Mason; Anders Krarup; C Patrick McClure; William L Irving; Jonathan K Ball; Mark Harris; Timothy P Hickling; Alexander W Tarr
Journal:  J Innate Immun       Date:  2014-05-15       Impact factor: 7.349

View more
  10 in total

Review 1.  Achieving cross-reactivity with pan-ebolavirus antibodies.

Authors:  Liam B King; Jacob C Milligan; Brandyn R West; Sharon L Schendel; Erica Ollmann Saphire
Journal:  Curr Opin Virol       Date:  2019-03-15       Impact factor: 7.090

Review 2.  The structural basis for filovirus neutralization by monoclonal antibodies.

Authors:  Liam B King; Brandyn R West; Sharon L Schendel; Erica Ollmann Saphire
Journal:  Curr Opin Immunol       Date:  2018-06-22       Impact factor: 7.486

3.  A new strategy for full-length Ebola virus glycoprotein expression in E.coli.

Authors:  Junjie Zai; Yinhua Yi; Han Xia; Bo Zhang; Zhiming Yuan
Journal:  Virol Sin       Date:  2016-12-16       Impact factor: 4.327

4.  Select membrane proteins modulate MNV-1 infection of macrophages and dendritic cells in a cell type-specific manner.

Authors:  Juliana Bragazzi Cunha; Christiane E Wobus
Journal:  Virus Res       Date:  2016-06-02       Impact factor: 3.303

5.  Ficolins do not alter host immune responses to lipopolysaccharide-induced inflammation in vivo.

Authors:  Ninette Genster; Olga Østrup; Camilla Schjalm; Tom Eirik Mollnes; Jack B Cowland; Peter Garred
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

6.  Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction.

Authors:  Anne-Laure Favier; Olivier Reynard; Evelyne Gout; Martin van Eijk; Henk P Haagsman; Erika Crouch; Viktor Volchkov; Christophe Peyrefitte; Nicole M Thielens
Journal:  Viruses       Date:  2018-12-26       Impact factor: 5.048

Review 7.  In the Crosshairs: RNA Viruses OR Complement?

Authors:  Nisha Asok Kumar; Umerali Kunnakkadan; Sabu Thomas; John Bernet Johnson
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

Review 8.  A double edged-sword - The Complement System during SARS-CoV-2 infection.

Authors:  Lazara Elena Santiesteban-Lores; Thais Akemi Amamura; Tiago Francisco da Silva; Leonardo Moura Midon; Milena Carvalho Carneiro; Lourdes Isaac; Lorena Bavia
Journal:  Life Sci       Date:  2021-02-17       Impact factor: 5.037

9.  Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.

Authors:  Jack Mellors; Tom Tipton; Sarah Katharina Fehling; Joseph Akoi Bore; Fara Raymond Koundouno; Yper Hall; Jacob Hudson; Frances Alexander; Stephanie Longet; Stephen Taylor; Andrew Gorringe; N'Faly Magassouba; Mandy Kader Konde; Julian Hiscox; Thomas Strecker; Miles Carroll
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

Review 10.  Complement Proteins as Soluble Pattern Recognition Receptors for Pathogenic Viruses.

Authors:  Valarmathy Murugaiah; Praveen M Varghese; Nazar Beirag; Syreeta De Cordova; Robert B Sim; Uday Kishore
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.